(Q54599564)

1 June 2018

title

Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. (English)

1 reference

1 June 2018

0 references

3

Toshihiko Doi

1 reference

1 June 2018

Atsushi Ohtsu

10

object named as

Atsushi Ohtsu

1 reference

1 June 2018

author name string

Akira Sawaki

1

1 reference

1 June 2018

Toshirou Nishida

2

1 reference

1 June 2018

Yasuhide Yamada

4

1 reference

1 June 2018

Yoshito Komatsu

5

1 reference

1 June 2018

Tatsuo Kanda

6

1 reference

1 June 2018

Yoshihiro Kakeji

7

1 reference

1 June 2018

Yusuke Onozawa

8

1 reference

1 June 2018

Makoto Yamasaki

9

1 reference

1 June 2018

language of work or name

English

0 references

publication date

31 March 2011

1 reference

1 June 2018

published in

Cancer

1 reference

1 June 2018

volume

117

1 reference

1 June 2018

issue

20

1 reference

1 June 2018

page(s)

4633-4641

1 reference

1 June 2018

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Molecular characterization of pediatric gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

hOCT 1 and resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Practical management of tyrosine kinase inhibitor-associated side effects in GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26120

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.26120

1 reference

1 June 2018

PubMed ID

21456006

1 reference

1 June 2018